Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC.ATOS · Entity 7556 | CFO, Gen Counsel and Secretary | March 02, 2023 | March 06, 2023 |
| CERENOME, INC.CNSY · Entity 7637 | Director | October 01, 2026 | October 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ATOSSA THERAPEUTICS, INC.
Report date March 02, 2023 · Filed March 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.72 · Expires 2033-03-02 | Direct | 557,900 |
Reported balance
After 2023-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-02 · Grant · Acquired 557,900 · Balance 557,900 F1: The option will vest and become exercisable on a quarterly basis over 24 months from the grant-date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest and become exercisable on a quarterly basis over 24 months from the grant-date.
CERENOME, INC.
Report date October 01, 2026 · Filed October 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,843 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Exercise / conversion · Acquired 921 · Balance 1,843 F2: Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments beginning on July 1, 2026. F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 1,843 |
Reported balance
After 2026-10-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-01 · Exercise / conversion · Disposed 921 · Balance 1,843 F2: Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments beginning on July 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock.
F2: Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments beginning on July 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 1, 2026 16:00 UTC | CERENOME, INC. CNSY · Entity 7637 | Exercise / conversionRestricted Stock Units · Derivative | 921 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-409855 · ownership.xml · derivative · entry 2 Guse Kyle · CIK 0001566618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,843 Underlying: Common Stock · 921 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments beginning on July 1, 2026. F2 · derivative.expiration_date: Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments beginning on July 1, 2026. Read SEC document |
| October 01, 2026 Filed Oct 1, 2026 16:00 UTC | CERENOME, INC. CNSY · Entity 7637 | Exercise / conversionCommon Stock | 921 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-409855 · ownership.xml · nonDerivative · entry 1 Guse Kyle · CIK 0001566618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,843 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments beginning on July 1, 2026. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock. Read SEC document |
| July 01, 2026 Filed Jul 1, 2026 20:30 UTC | CERENOME, INC. PSTV · Entity 7637 | Exercise / conversionRestricted Stock Units · Derivative | 922 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-292644 · ownership.xml · derivative · entry 2 Guse Kyle · CIK 0001566618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,764 Underlying: Common Stock · 922 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments beginning on July 1, 2026. F2 · derivative.expiration_date: Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments beginning on July 1, 2026. Read SEC document |
| July 01, 2026 Filed Jul 1, 2026 20:30 UTC | CERENOME, INC. PSTV · Entity 7637 | Exercise / conversionCommon Stock | 922 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-292644 · ownership.xml · nonDerivative · entry 1 Guse Kyle · CIK 0001566618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 922 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments beginning on July 1, 2026. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:11 UTC | CERENOME, INC. PSTV · Entity 7637 | GrantStock Option (Right to Buy) · Derivative | 3,686 | $0.00 Strike: $5.76 | $0.00 |
DisclosureSEC source: 0001193125-26-228929 · ownership.xml · derivative · entry 2 Guse Kyle · CIK 0001566618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,686 Underlying: Common Stock · 3,686 shares Expires 2036-05-14 F2 · derivative.exercise_date: The options vest monthly over 12 months from the grant date in substantially equal monthly increments, provided that the options vest in full on the Issuer's 2027 Annual Stockholder Meeting, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date or, if earlier, such annual meeting. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:11 UTC | CERENOME, INC. PSTV · Entity 7637 | GrantRestricted Stock Units · Derivative | 3,686 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-228929 · ownership.xml · derivative · entry 1 Guse Kyle · CIK 0001566618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,686 Underlying: Common Stock · 3,686 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs awarded vest ratably over four quarters in substantially equal 1/4th increments, commencing with 1/4th vesting on July 1, 2026 and the remainder vesting quarterly thereafter. F1 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs awarded vest ratably over four quarters in substantially equal 1/4th increments, commencing with 1/4th vesting on July 1, 2026 and the remainder vesting quarterly thereafter. F1 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs awarded vest ratably over four quarters in substantially equal 1/4th increments, commencing with 1/4th vesting on July 1, 2026 and the remainder vesting quarterly thereafter. Read SEC document |
| August 13, 2025 Filed Aug 15, 2025 20:29 UTC | CERENOME, INC. PSTV · Entity 7637 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0000950170-25-109414 · ownership.xml · derivative · entry 2 Guse Kyle · CIK 0001566618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-08-12 F2 · derivative.exercise_date: The options vest monthly over 24 months from the Grant Date in substantially equal monthly installments. Read SEC document |
| August 13, 2025 Filed Aug 15, 2025 20:29 UTC | CERENOME, INC. PSTV · Entity 7637 | GrantStock Option (Right to Buy) · Derivative | 297,794 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0000950170-25-109414 · ownership.xml · derivative · entry 1 Guse Kyle · CIK 0001566618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 297,794 Underlying: Common Stock · 297,794 shares Expires 2035-08-12 F1 · derivative.exercise_date: The options vest monthly over 12 months from the Grant Date in substantially equal monthly installments, provided that the options vest in full on the Issuer's 2026 Annual Stockholder Meeting, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date or, if earlier, such annual meeting. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 21:10 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 557,900 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001437749-23-005531 · rdgdoc.xml · derivative · entry 1 Guse Kyle · CIK 0001566618 · CFO, Gen Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 557,900 Underlying: Common Stock · 557,900 shares Expires 2033-03-02 F1 · derivative.exercise_date: The option will vest and become exercisable on a quarterly basis over 24 months from the grant-date. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 22:15 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 746,667 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001437749-22-004668 · rdgdoc.xml · derivative · entry 1 Guse Kyle · CIK 0001566618 · CFO, Gen Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 746,667 Underlying: Common Stock · 746,667 shares Expires 2032-02-24 F1 · derivative.exercise_date: The options will vest on a quarterly basis over two (2) years. Read SEC document |
| May 14, 2021 Filed May 18, 2021 20:18 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 850,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001437749-21-012675 · rdgdoc.xml · derivative · entry 1 Guse Kyle · CIK 0001566618 · CFO, Gen Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 850,000 Underlying: Common Stock · 850,000 shares Expires 2031-05-14 F1 · derivative.exercise_date: The options will vest on a quarterly basis over the next 24 months. Option grant was issued at 4:30 p.m. (ET) on May 14, 2021 with an exercise price of $2.90, representing the most recently reported closing stock price at the time of grant. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 22:21 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (Right to Buy) · Derivative | 395,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001437749-20-007630 · rdgdoc.xml · derivative · entry 2 Guse Kyle · CIK 0001566618 · CFO, Gen Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395,000 Underlying: Common Shares · 395,000 shares Expires 2030-04-09 F2 · derivative.exercise_date: The options will vest quarterly in equal amounts over two years from the grant date (April 9, 2020), subject to continued employment with the Company through the applicable vesting dates. However, 50% of all then-unvested options will vest immediately upon the achievement of certain milestones. The stock options are also subject to stockholder approval of the 2020 Stock Incentive Plan of the Company, which approval must occur within one year from the grant date. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 22:21 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (Right to Buy) · Derivative | 195,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001437749-20-007630 · rdgdoc.xml · derivative · entry 1 Guse Kyle · CIK 0001566618 · CFO, Gen Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Shares · 195,000 shares Expires 2030-04-09 F1 · derivative.exercise_date: The options will vest quarterly in equal amounts over two years from the grant date (April 9, 2020), subject to continued employment with the Company through the applicable vesting dates. Read SEC document |
| January 13, 2019 Filed Jan 15, 2019 21:10 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (Right to Buy) · Derivative | 800,000 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001615774-19-000644 · s115378_form4.xml · derivative · entry 2 Guse Kyle · CIK 0001566618 · CFO, Gen Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,000 Underlying: Common Shares · 800,000 shares Expires 2029-01-13 F1 · kind: The June 27, 2018 options are being rescinded and a new option is being granted in order to: (i) impose a shareholder-approval requirement for the new option grant, and (ii) remove the cash settlement feature and associated liability from the June 27, 2018 grant. F3 · derivative.exercise_date: Subject to stockholder approval of the option grant, the option will vest and be exercisable with respect to: (i) 25% of the underlying shares as of the grant date (January 13, 2019), (ii) 50% of the underlying shares over a two-year period (vesting ratably quarterly) from June 27, 2018, and (iii) 25% of the underlying shares upon achievement of certain milestones. If the option grant is not approved by stockholders, then the option will not be exercisable. Read SEC document |
| January 13, 2019 Filed Jan 15, 2019 21:10 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | Disposition to issuerStock Option (Right to Buy) · Derivative | 700,000 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0001615774-19-000644 · s115378_form4.xml · derivative · entry 1 Guse Kyle · CIK 0001566618 · CFO, Gen Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 700,000 shares Expires 2028-06-27 F1 · kind: The June 27, 2018 options are being rescinded and a new option is being granted in order to: (i) impose a shareholder-approval requirement for the new option grant, and (ii) remove the cash settlement feature and associated liability from the June 27, 2018 grant. F2 · derivative.exercise_date: Twenty-five percent of the options were vested as of the grant date (June 27, 2018), 50% of the options will vest quarterly over two years from the grant date, and the remaining 25% will vest upon achievement of certain milestones. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 20:04 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 700,000 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0001615774-18-006001 · s111134_form4.xml · derivative · entry 1 Guse Kyle · CIK 0001566618 · CFO, Gen Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2028-06-27 F1 · derivative.exercise_date: Twenty-five percent of the options have vested as of the grant date, 50% of the options will vest quarterly over two years, and the remaining 25% will vest upon achievement of certain milestones. Read SEC document |
| May 30, 2018 Filed May 31, 2018 19:24 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | PurchaseWarrants · Derivative | 2,272 | $1,000.00 Strike: $4.05 | $2,272,000.00 |
DisclosureSEC source: 0001615774-18-004655 · s110545_form4.xml · derivative · entry 2 Guse Kyle · CIK 0001566618 · CFO, Gen Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,272 Underlying: Common Stock · 2,272 shares Expires 2022-05-30 F4 · price: Shares of Series B Convertible Preferred Stock and Warrants were issued as part of a unit, with each unit consisting of one share of Series B Convertible Preferred Stock and 284 Warrants. Read SEC document |
| May 30, 2018 Filed May 31, 2018 19:24 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | PurchaseSeries B Convertible Preferred Stock · Derivative | 8 | $1,000.00 Strike: $3.52 | $8,000.00 |
DisclosureSEC source: 0001615774-18-004655 · s110545_form4.xml · derivative · entry 1 Guse Kyle · CIK 0001566618 · CFO, Gen Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8 Underlying: Common Stock · 2,273 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock is convertible into the number of shares of Common Stock equal to the stated value of $1,000 divided by $3.52. F4 · price: Shares of Series B Convertible Preferred Stock and Warrants were issued as part of a unit, with each unit consisting of one share of Series B Convertible Preferred Stock and 284 Warrants. F2 · derivative.expiration_date: Shares of Series B Convertible Preferred Stock do not expire. F3 · derivative.underlying_shares: No fractional shares will be issued upon conversion. At its election, the Company will either issue a cash adjustment or round up to the next whole share. The number reflected here assumes rounding up to the next whole share. Read SEC document |
| November 15, 2017 Filed Nov 16, 2017 11:03 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | PurchaseCommon Stock | 1,400 | $0.34 | $471.10 |
DisclosureSEC source: 0001615774-17-006777 · s108207_form4.xml · nonDerivative · entry 2 Guse Kyle · CIK 0001566618 · CFO, Gen Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| November 15, 2017 Filed Nov 16, 2017 11:03 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | PurchaseCommon Stock | 8,600 | $0.34 | $2,898.20 |
DisclosureSEC source: 0001615774-17-006777 · s108207_form4.xml · nonDerivative · entry 1 Guse Kyle · CIK 0001566618 · CFO, Gen Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,600 Read SEC document |
| May 24, 2017 Filed May 26, 2017 17:46 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 495,333 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001615774-17-002741 · s106362_form4.xml · derivative · entry 1 Guse Kyle · CIK 0001566618 · CFO, Gen Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 640,667 Underlying: Common Stock · 495,333 shares Expires 2027-05-24 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over the next 48 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.